Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $13.8 million.

  • Krystal Biotech's Share-based Compensation rose 305.48% to $13.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $54.5 million, marking a year-over-year increase of 1096.55%. This contributed to the annual value of $54.5 million for FY2025, which is 1096.55% up from last year.
  • As of Q4 2025, Krystal Biotech's Share-based Compensation stood at $13.8 million, which was up 305.48% from $13.2 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Share-based Compensation ranged from a high of $14.1 million in Q2 2025 and a low of $2.3 million during Q1 2021
  • Its 5-year average for Share-based Compensation is $9.6 million, with a median of $9.7 million in 2022.
  • As far as peak fluctuations go, Krystal Biotech's Share-based Compensation surged by 17799.39% in 2022, and later tumbled by 1090.35% in 2024.
  • Krystal Biotech's Share-based Compensation (Quarter) stood at $5.1 million in 2021, then surged by 85.66% to $9.6 million in 2022, then increased by 3.15% to $9.9 million in 2023, then surged by 35.55% to $13.4 million in 2024, then increased by 3.05% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q4 2025, $13.2 million for Q3 2025, and $14.1 million during Q2 2025.